Nivolumab significantly prolongs survival, versus placebo, in heavily pretreated patients with unresectable gastric or gastro-esophageal junction cancer, ATTRACTION-2 study findings indicate.
Narikazu Boku (National Cancer Center Hospital, Tokyo, Japan) and co-researchers say their results suggest that nivolumab “might be a new treatment option” for these patients, who currently have no standard of care therapy available and typically have poor prognosis.
https://www.medwirenews.com/oncology/gastrointestinal-cancer/nivolumab-represents-new-treatment-option-for-advanced-gastric-c/15151508

Nivolumab significantly prolongs survival, versus placebo, in heavily pretreated patients with unresectable gastric or gastro-esophageal junction cancer, ATTRACTION-2 study findings indicate.
Narikazu Boku (National Cancer Center Hospital, Tokyo, Japan) and co-researchers say their results suggest that nivolumab “might be a new treatment option” for these patients, who currently have no standard of care therapy available and typically have poor prognosis.
https://www.medwirenews.com/oncology/gastrointestinal-cancer/nivolumab-represents-new-treatment-option-for-advanced-gastric-c/15151508